New drug shows promise for rare amyloidosis in early trial
NCT ID NCT07524634
First seen Apr 23, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tests an experimental drug called elranatamab for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. The drug helps the immune system attack the faulty cells causing the disease. About 64 participants will receive injections over 6 months and be followed for up to 2 years to see if the drug can produce deep remissions and improve organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID LIGHT-CHAIN AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.